Cargando…

Direct administration of the non-competitive interleukin-1 receptor antagonist rytvela transiently reduced intrauterine inflammation in an extremely preterm sheep model of chorioamnionitis

BACKGROUND: Intraamniotic inflammation is associated with up to 40% of preterm births, most notably in deliveries occurring prior to 32 weeks’ gestation. Despite this, there are few treatment options allowing the prevention of preterm birth and associated fetal injury. Recent studies have shown that...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Yuki, Saito, Masatoshi, Usuda, Haruo, Takahashi, Tsukasa, Watanabe, Shimpei, Hanita, Takushi, Sato, Shinichi, Kumagai, Yusaku, Koshinami, Shota, Ikeda, Hideyuki, Carter, Sean, Fee, Erin L., Furfaro, Lucy, Chemtob, Sylvain, Keelan, Jeffrey, Olson, David, Yaegashi, Nobuo, Newnham, John P., Jobe, Alan H., Kemp, Matthew W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462743/
https://www.ncbi.nlm.nih.gov/pubmed/34559862
http://dx.doi.org/10.1371/journal.pone.0257847
_version_ 1784572262521765888
author Takahashi, Yuki
Saito, Masatoshi
Usuda, Haruo
Takahashi, Tsukasa
Watanabe, Shimpei
Hanita, Takushi
Sato, Shinichi
Kumagai, Yusaku
Koshinami, Shota
Ikeda, Hideyuki
Carter, Sean
Fee, Erin L.
Furfaro, Lucy
Chemtob, Sylvain
Keelan, Jeffrey
Olson, David
Yaegashi, Nobuo
Newnham, John P.
Jobe, Alan H.
Kemp, Matthew W.
author_facet Takahashi, Yuki
Saito, Masatoshi
Usuda, Haruo
Takahashi, Tsukasa
Watanabe, Shimpei
Hanita, Takushi
Sato, Shinichi
Kumagai, Yusaku
Koshinami, Shota
Ikeda, Hideyuki
Carter, Sean
Fee, Erin L.
Furfaro, Lucy
Chemtob, Sylvain
Keelan, Jeffrey
Olson, David
Yaegashi, Nobuo
Newnham, John P.
Jobe, Alan H.
Kemp, Matthew W.
author_sort Takahashi, Yuki
collection PubMed
description BACKGROUND: Intraamniotic inflammation is associated with up to 40% of preterm births, most notably in deliveries occurring prior to 32 weeks’ gestation. Despite this, there are few treatment options allowing the prevention of preterm birth and associated fetal injury. Recent studies have shown that the small, non-competitive allosteric interleukin (IL)-1 receptor inhibitor, rytvela, may be of use in resolving inflammation associated with preterm birth (PTB) and fetal injury. We aimed to use an extremely preterm sheep model of chorioamnionitis to investigate the anti-inflammatory efficacy of rytvela in response to established intra-amniotic (IA) lipopolysaccharide (LPS) exposure. We hypothesized that rytvela would reduce LPS-induced IA inflammation in amniotic fluid (AF) and fetal tissues. METHODS: Sheep with a single fetus at 95 days gestation (estimated fetal weight 1.0 kg) had surgery to place fetal jugular and IA catheters. Animals were recovered for 48 hours before being randomized to either: i) IA administration of 2 ml saline 24 hours before 2 ml IA and 2 ml fetal intravenous (IV) administration of saline (Saline Group, n = 7); ii) IA administration of 10 mg LPS in 2 ml saline 24 hours before 2 ml IA and 2 ml fetal IV saline (LPS Group, n = 10); 3) IA administration of 10 mg LPS in 2 ml saline 24 hours before 0.3 mg/fetal kg IA and 1 mg/fetal kg fetal IV rytvela in 2 ml saline, respectively (LPS + rytvela Group, n = 7). Serial AF samples were collected for 120 h. Inflammatory responses were characterized by quantitative polymerase chain reaction (qPCR), histology, fluorescent immunohistochemistry, enzyme-linked inmmunosorbent assay (ELISA), fluorescent western blotting and blood chemistry analysis. RESULTS: LPS-treated animals had endotoxin and AF monocyte chemoattractant protein (MCP)-1 concentrations that were significantly higher at 24 hours (immediately prior to rytvela administration) relative to values from Saline Group animals. Following rytvela administration, the average MCP-1 concentrations in the AF were significantly lower in the LPS + rytvela Group relative to in the LPS Group. In delivery samples, the expression of IL-1β in fetal skin was significantly lower in the LPS + rytvela Group compared to the LPS Group. CONCLUSION: A single dose of rytvela was associated with partial, modest inhibition in the expression of a panel of cytokines/chemokines in fetal tissues undergoing an active inflammatory response.
format Online
Article
Text
id pubmed-8462743
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-84627432021-09-25 Direct administration of the non-competitive interleukin-1 receptor antagonist rytvela transiently reduced intrauterine inflammation in an extremely preterm sheep model of chorioamnionitis Takahashi, Yuki Saito, Masatoshi Usuda, Haruo Takahashi, Tsukasa Watanabe, Shimpei Hanita, Takushi Sato, Shinichi Kumagai, Yusaku Koshinami, Shota Ikeda, Hideyuki Carter, Sean Fee, Erin L. Furfaro, Lucy Chemtob, Sylvain Keelan, Jeffrey Olson, David Yaegashi, Nobuo Newnham, John P. Jobe, Alan H. Kemp, Matthew W. PLoS One Research Article BACKGROUND: Intraamniotic inflammation is associated with up to 40% of preterm births, most notably in deliveries occurring prior to 32 weeks’ gestation. Despite this, there are few treatment options allowing the prevention of preterm birth and associated fetal injury. Recent studies have shown that the small, non-competitive allosteric interleukin (IL)-1 receptor inhibitor, rytvela, may be of use in resolving inflammation associated with preterm birth (PTB) and fetal injury. We aimed to use an extremely preterm sheep model of chorioamnionitis to investigate the anti-inflammatory efficacy of rytvela in response to established intra-amniotic (IA) lipopolysaccharide (LPS) exposure. We hypothesized that rytvela would reduce LPS-induced IA inflammation in amniotic fluid (AF) and fetal tissues. METHODS: Sheep with a single fetus at 95 days gestation (estimated fetal weight 1.0 kg) had surgery to place fetal jugular and IA catheters. Animals were recovered for 48 hours before being randomized to either: i) IA administration of 2 ml saline 24 hours before 2 ml IA and 2 ml fetal intravenous (IV) administration of saline (Saline Group, n = 7); ii) IA administration of 10 mg LPS in 2 ml saline 24 hours before 2 ml IA and 2 ml fetal IV saline (LPS Group, n = 10); 3) IA administration of 10 mg LPS in 2 ml saline 24 hours before 0.3 mg/fetal kg IA and 1 mg/fetal kg fetal IV rytvela in 2 ml saline, respectively (LPS + rytvela Group, n = 7). Serial AF samples were collected for 120 h. Inflammatory responses were characterized by quantitative polymerase chain reaction (qPCR), histology, fluorescent immunohistochemistry, enzyme-linked inmmunosorbent assay (ELISA), fluorescent western blotting and blood chemistry analysis. RESULTS: LPS-treated animals had endotoxin and AF monocyte chemoattractant protein (MCP)-1 concentrations that were significantly higher at 24 hours (immediately prior to rytvela administration) relative to values from Saline Group animals. Following rytvela administration, the average MCP-1 concentrations in the AF were significantly lower in the LPS + rytvela Group relative to in the LPS Group. In delivery samples, the expression of IL-1β in fetal skin was significantly lower in the LPS + rytvela Group compared to the LPS Group. CONCLUSION: A single dose of rytvela was associated with partial, modest inhibition in the expression of a panel of cytokines/chemokines in fetal tissues undergoing an active inflammatory response. Public Library of Science 2021-09-24 /pmc/articles/PMC8462743/ /pubmed/34559862 http://dx.doi.org/10.1371/journal.pone.0257847 Text en © 2021 Takahashi et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Takahashi, Yuki
Saito, Masatoshi
Usuda, Haruo
Takahashi, Tsukasa
Watanabe, Shimpei
Hanita, Takushi
Sato, Shinichi
Kumagai, Yusaku
Koshinami, Shota
Ikeda, Hideyuki
Carter, Sean
Fee, Erin L.
Furfaro, Lucy
Chemtob, Sylvain
Keelan, Jeffrey
Olson, David
Yaegashi, Nobuo
Newnham, John P.
Jobe, Alan H.
Kemp, Matthew W.
Direct administration of the non-competitive interleukin-1 receptor antagonist rytvela transiently reduced intrauterine inflammation in an extremely preterm sheep model of chorioamnionitis
title Direct administration of the non-competitive interleukin-1 receptor antagonist rytvela transiently reduced intrauterine inflammation in an extremely preterm sheep model of chorioamnionitis
title_full Direct administration of the non-competitive interleukin-1 receptor antagonist rytvela transiently reduced intrauterine inflammation in an extremely preterm sheep model of chorioamnionitis
title_fullStr Direct administration of the non-competitive interleukin-1 receptor antagonist rytvela transiently reduced intrauterine inflammation in an extremely preterm sheep model of chorioamnionitis
title_full_unstemmed Direct administration of the non-competitive interleukin-1 receptor antagonist rytvela transiently reduced intrauterine inflammation in an extremely preterm sheep model of chorioamnionitis
title_short Direct administration of the non-competitive interleukin-1 receptor antagonist rytvela transiently reduced intrauterine inflammation in an extremely preterm sheep model of chorioamnionitis
title_sort direct administration of the non-competitive interleukin-1 receptor antagonist rytvela transiently reduced intrauterine inflammation in an extremely preterm sheep model of chorioamnionitis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462743/
https://www.ncbi.nlm.nih.gov/pubmed/34559862
http://dx.doi.org/10.1371/journal.pone.0257847
work_keys_str_mv AT takahashiyuki directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT saitomasatoshi directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT usudaharuo directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT takahashitsukasa directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT watanabeshimpei directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT hanitatakushi directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT satoshinichi directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT kumagaiyusaku directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT koshinamishota directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT ikedahideyuki directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT cartersean directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT feeerinl directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT furfarolucy directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT chemtobsylvain directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT keelanjeffrey directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT olsondavid directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT yaegashinobuo directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT newnhamjohnp directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT jobealanh directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis
AT kempmattheww directadministrationofthenoncompetitiveinterleukin1receptorantagonistrytvelatransientlyreducedintrauterineinflammationinanextremelypretermsheepmodelofchorioamnionitis